$494 Million is the total value of Ghost Tree Capital, LLC's 53 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 457.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | New | INCYTE CORPput | $83,330,000 | – | 8,333 | +100.0% | 16.86% | – |
| IMMU | Buy | IMMUNOMEDICS INC | $27,029,000 | +8.8% | 1,850,000 | +20.3% | 5.47% | -6.2% |
| ECYT | New | ENDOCYTE INC | $19,998,000 | – | 2,200,000 | +100.0% | 4.05% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $17,411,000 | – | 235,000 | +100.0% | 3.52% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $16,900,000 | – | 1,000,000 | +100.0% | 3.42% | – |
| AVXS | Buy | AVEXIS INC | $16,683,000 | +77.3% | 135,000 | +58.8% | 3.38% | +53.0% |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $15,938,000 | – | 850,000 | +100.0% | 3.22% | – |
| MYL | Buy | MYLAN N V | $14,410,000 | +36.2% | 350,000 | +40.0% | 2.92% | +17.5% |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO L | $14,168,000 | +183.9% | 550,000 | +197.3% | 2.87% | +145.0% |
| CBIO | New | CATALYST BIOSCIENCES INC | $11,610,000 | – | 450,000 | +100.0% | 2.35% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $11,280,000 | – | 750,000 | +100.0% | 2.28% | – |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $9,082,000 | +101.2% | 950,000 | +90.0% | 1.84% | +73.5% |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $9,075,000 | – | 500,000 | +100.0% | 1.84% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $8,988,000 | – | 400,000 | +100.0% | 1.82% | – |
| CNCE | New | CONCERT PHARMACEUTICALS INC | $8,015,000 | – | 350,000 | +100.0% | 1.62% | – |
| ADMS | New | ADAMAS PHARMACEUTICALS INC | $7,766,000 | – | 325,000 | +100.0% | 1.57% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $7,371,000 | – | 150,000 | +100.0% | 1.49% | – |
| RTRX | New | RETROPHIN INC | $7,029,000 | – | 314,367 | +100.0% | 1.42% | – |
| KDMN | Buy | KADMON HLDGS INC | $6,800,000 | +168.4% | 1,600,000 | +128.6% | 1.38% | +131.6% |
| AVDL | New | AVADEL PHARMACEUTICALS PLCsponsored adr | $6,197,000 | – | 850,000 | +100.0% | 1.25% | – |
| ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $5,768,000 | – | 800,000 | +100.0% | 1.17% | – |
| GTHX | New | G1 THERAPEUTICS INC | $5,558,000 | – | 150,000 | +100.0% | 1.12% | – |
| PTCT | New | PTC THERAPEUTICS INC | $5,412,000 | – | 200,000 | +100.0% | 1.10% | – |
| NEOS | Buy | NEOS THERAPEUTICS INC | $4,980,000 | +62.7% | 600,000 | +100.0% | 1.01% | +40.4% |
| ADRO | New | ADURO BIOTECH INC | $4,650,000 | – | 500,000 | +100.0% | 0.94% | – |
| FXF | New | CURRENCYSHARES SWISS FRANC Tswiss franc sh | $4,507,000 | – | 45,800 | +100.0% | 0.91% | – |
| MRSN | New | MERSANA THERAPEUTICS INC | $4,388,000 | – | 278,244 | +100.0% | 0.89% | – |
| TGTX | New | TG THERAPEUTICS INC | $4,260,000 | – | 300,000 | +100.0% | 0.86% | – |
| GLYC | New | GLYCOMIMETICS INC | $4,058,000 | – | 250,000 | +100.0% | 0.82% | – |
| LCI | New | LANNET INC | $4,013,000 | – | 250,000 | +100.0% | 0.81% | – |
| INFI | New | INFINITY PHARMACEUTICALS INC | $3,675,000 | – | 1,750,000 | +100.0% | 0.74% | – |
| TSRO | New | TESARO INC | $3,537,000 | – | 61,900 | +100.0% | 0.72% | – |
| SLDB | New | SOLID BIOSCIENCES INC | $2,888,000 | – | 385,000 | +100.0% | 0.58% | – |
| JNCE | New | JOUNCE THERAPEUTICS INC | $2,796,000 | – | 125,092 | +100.0% | 0.57% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO Lcall | $1,935,000 | – | 75,100 | +100.0% | 0.39% | – |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $1,030,000 | – | 76,786 | +100.0% | 0.21% | – |
| ANAB | New | ANAPTYSBIO INC | $937,000 | – | 9,000 | +100.0% | 0.19% | – |
| MOTS | New | MOTUS GI HLDGS INC | $448,000 | – | 100,000 | +100.0% | 0.09% | – |
| IMGN | New | IMMUNOGEN INC | $225,000 | – | 7,500 | +100.0% | 0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ASCENDIS PHARMA A/S - ADR | 30 | Q2 2024 | 11.8% |
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| SAREPTA THERAPEUTICS INC | 25 | Q2 2024 | 9.1% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SPDR SER TR | 22 | Q1 2024 | 16.9% |
| ARVINAS INC | 19 | Q2 2024 | 4.3% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SYNDAX PHARMACEUTICALS INC | 18 | Q2 2024 | 6.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-16 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.